Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma.

P A van Dam, I B Vergote, D G Lowe, J V Watson, P van Damme, J C van der Auwera, J H Shepherd

Gynaecological Oncology Unit, St Bartholomew's Hospital, London.

AIMS--To assess whether the overexpression of five dominant oncogene encoded proteins is crucial to the pathogenesis of ovarian carcinoma and whether this provides any useful prognostic information. METHODS--The expression of the insulin-like growth factor 1 receptor (ILGFR 1), epidermal growth factor receptor (EGFR), and the c-erbB-2, c-ras, and c-myc products was studied by multiparameter flow cytometry in 80 patients with epithelial ovarian cancer for whom long term follow up was available. RESULTS--Overexpression of ILGFR 1, EGFR, c-erbB-2, c-ras and c-myc was found in, respectively, nine of 80 (11%), 10 of 80 (12%), 19 of 80 (24%), 16 of 80 (20%) and 28 of 80 (35%) ovarian carcinomas. The levels of expression of ILGFR 1, EGFR, c-erbB-2 and c-ras were significantly higher in the tumours of patients with recurrent or persistent disease after chemotherapy than in the tumours of patients at initial presentation (p < 0.02). Multivariate analysis showed that residual tumour (p < 0.001), FIGO stage (p = 0.002), EGFR overexpression (p = 0.030) and previous chemotherapy (p = 0.034) were independent variables for predicting survival. CONCLUSIONS--Overexpression of these oncoproteins only occurs in a small proportion of ovarian carcinomas but may have an important role in the progression of the disease.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Eckstein, N., Servan, K., Hildebrandt, B., Politz, A., Jonquieres, G. v., Wolf-Kummeth, S., Napierski, I., Hamacher, A., Kassack, M. U., Budczies, J., Beier, M., Dietel, M., Royer-Pokora, B., Denkert, C., Royer, H.-D. (2009). Hyperactivation of the Insulin-like Growth Factor Receptor I Signaling Pathway Is an Essential Event for Cisplatin Resistance of Ovarian Cancer Cells. Cancer Res. 69: 2996-3003 [Abstract] [Full Text]  
• Plisiecka-Halasa, J., Karpinska, G., Szymanska, T., Ziolkowska, I., Madry, R., Timorek, A., Debniak, J., Ulanska, M., Jedryka, M., Chudecka-Glaz, A., Klimek, M., Rembiszewska, A., Kraszewska, E., Dybowski, B., Markowska, J., Emerich, J., Pluzanska, A., Goluda, M., Rzepka-Gorska, I., Urbanski, K., Zielinski, J., Stelmachow, J., Chrabowska, M., Kupryjanczyk, J. (2003). P21WAF1, P27KIP1, TP53 and C-MYC analysis in 204 ovarian carcinomas treated with platinum-based regimens. Ann Oncol 14: 1078-1085 [Abstract] [Full Text]  
• Reinmuth, N., Liu, W., Fan, F., Jung, Y. D., Ahmad, S. A., Stoeltzing, O., Bucana, C. D., Radinsky, R., Ellis, L. M. (2002). Blockade of Insulin-like Growth Factor I Receptor Function Inhibits Growth and Angiogenesis of Colon Cancer. Clin. Cancer Res. 8: 3259-3269 [Abstract] [Full Text]  
• Auersperg, N., Wong, A. S. T., Choi, K.-C., Kang, S. K., Leung, P. C. K. (2001). Ovarian Surface Epithelium: Biology, Endocrinology, and Pathology. Endocr. Rev. 22: 255-288 [Abstract] [Full Text]  
• Montgomery, R. B., Guzman, J., O'Rourke, D. M., Stahl, W. L. (2000). Expression of Oncogenic Epidermal Growth Factor Receptor Family Kinases Induces Paclitaxel Resistance and Alters beta -Tubulin Isotype Expression. J. Biol. Chem. 275: 17358-17363 [Abstract] [Full Text]